drugset / Trial / NCT05701306
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Phase 1
Recruiting
100 enrolled
Ascentage Pharma Group Inc.
Suzhou Yasheng Pharmaceutical Co., Ltd. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
An open, non-randomized Phase I trial of dose-escalation and cohorts expansion to evaluate the safety, pharmacokinetic profile and initial efficacy of APG-115 alone or in combination with APG-2575 in the treatment of recurrent or refractory pediatric neuroblastoma or solid tumors.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2026-06-01
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | APG-2575 | Small molecule | — | Oral |
| Subject | Alrizomadlin | Small molecule | — | Oral |